日本語フィールド
著者：○Koichiro Takahashi, Hiroki Tashiro, Ryo Tajiri, Ayako Takamori, Masaru Uchida, Go Kato, Yuki Kurihara, Hironori Sadamatsu, Takashi Kinoshita, Makoto Yoshida, Atsushi Kawaguchi, Shinya Kimura, Naoko Sueoka-Aragane, Tomotaka Kawayama, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group題名：Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease発表情報：Int J Chron Obstruct Pulmon Dis 巻: 16 ページ: 3297-3307キーワード：chronic obstructive pulmonary disease; long-acting beta 2 agonist; long-acting muscarinic antagonist; physical activity; sedentary time概要：Background: Prolonged sedentary behavior is associated with worse prognosis in patients with chronic obstructive pulmonary disease (COPD). Our previous study found that first-line dual therapy with tiotropium/olodaterol significantly reduces sedentary time compared to tiotropium monotherapy in Japanese patients with treatment-na?ve COPD, although the characteristics of responders to dual-therapy versus monotherapy for COPD are still unclear.
Methods: Patients with treatment-na?ve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Physical activity was assessed using a triaxle accelerometer for 2 weeks before and after treatment. This analysis focused on the change in sedentary time, indicated by physical activity of 1.0-1.5 metabolic equivalents (METs), with stratification for the following factors: age, body mass index (BMI), pulmonary function, COPD assessment test (CAT), the 6-minute walk distance (6MWD), and physical activity level at study entry.
Results: Thirty-five patients received tiotropium/olodaterol and 34 patients received tiotropium. In patients with lower inspiratory capacity at study entry, a significant reduction in sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -12.8 ± 13.5 min, Tio/Olo: -65.1 ± 21.0 min, mean difference, -52.2 min, 95% CI -103.6 to 0.88, p = 0.046). In patients with a shorter duration of physical activity of ?2 METs at study entry, a significant reduction of sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -3.3 ± 17.5 min, Tio/Olo: -72.9 ± 23.1 min, mean difference, -69.7 min, 95% CI -128.7 to -10.6, p = 0.02). There were no differences in terms of age, BMI, CAT score, 6MWD, FEV1, FVC, VC, and physical activity of 1.0-1.5 METs and ?3.0 METs.
Conclusion: This study showed that COPD patients with lower inspiratory capacity or shorter active time of ?2.0 METs at study entry are likely to exhibit significantly greater reduction in sedentary time with tiotropium/olodaterol treatment.抄録：英語フィールド
Author：○Koichiro Takahashi, Hiroki Tashiro, Ryo Tajiri, Ayako Takamori, Masaru Uchida, Go Kato, Yuki Kurihara, Hironori Sadamatsu, Takashi Kinoshita, Makoto Yoshida, Atsushi Kawaguchi, Shinya Kimura, Naoko Sueoka-Aragane, Tomotaka Kawayama, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator GroupTitle：Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary DiseaseAnnouncement information:Int J Chron Obstruct Pulmon Dis Vol: 16 Page: 3297-3307Keyword：chronic obstructive pulmonary disease; long-acting beta 2 agonist; long-acting muscarinic antagonist; physical activity; sedentary timeAn abstract：Background: Prolonged sedentary behavior is associated with worse prognosis in patients with chronic obstructive pulmonary disease (COPD). Our previous study found that first-line dual therapy with tiotropium/olodaterol significantly reduces sedentary time compared to tiotropium monotherapy in Japanese patients with treatment-na?ve COPD, although the characteristics of responders to dual-therapy versus monotherapy for COPD are still unclear.
Methods: Patients with treatment-na?ve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Physical activity was assessed using a triaxle accelerometer for 2 weeks before and after treatment. This analysis focused on the change in sedentary time, indicated by physical activity of 1.0-1.5 metabolic equivalents (METs), with stratification for the following factors: age, body mass index (BMI), pulmonary function, COPD assessment test (CAT), the 6-minute walk distance (6MWD), and physical activity level at study entry.
Results: Thirty-five patients received tiotropium/olodaterol and 34 patients received tiotropium. In patients with lower inspiratory capacity at study entry, a significant reduction in sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -12.8 ± 13.5 min, Tio/Olo: -65.1 ± 21.0 min, mean difference, -52.2 min, 95% CI -103.6 to 0.88, p = 0.046). In patients with a shorter duration of physical activity of ?2 METs at study entry, a significant reduction of sedentary time was observed in the tiotropium/olodaterol group compared with the tiotropium group (Tio: -3.3 ± 17.5 min, Tio/Olo: -72.9 ± 23.1 min, mean difference, -69.7 min, 95% CI -128.7 to -10.6, p = 0.02). There were no differences in terms of age, BMI, CAT score, 6MWD, FEV1, FVC, VC, and physical activity of 1.0-1.5 METs and ?3.0 METs.
Conclusion: This study showed that COPD patients with lower inspiratory capacity or shorter active time of ?2.0 METs at study entry are likely to exhibit significantly greater reduction in sedentary time with tiotropium/olodaterol treatment.